A detailed history of Sherbrooke Park Advisers LLC transactions in Exelixis, Inc. stock. As of the latest transaction made, Sherbrooke Park Advisers LLC holds 31,301 shares of EXEL stock, worth $1.13 Million. This represents 0.19% of its overall portfolio holdings.

Number of Shares
31,301
Holding current value
$1.13 Million
% of portfolio
0.19%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$21.96 - $27.6 $687,369 - $863,907
31,301 New
31,301 $812 Million
Q1 2024

May 15, 2024

SELL
$20.17 - $23.93 $46,310 - $54,943
-2,296 Reduced 20.89%
8,696 $206 Million
Q4 2023

Feb 14, 2024

SELL
$19.25 - $24.13 $1.62 Million - $2.03 Million
-84,326 Reduced 88.47%
10,992 $264 Million
Q3 2023

Nov 14, 2023

BUY
$19.04 - $22.74 $1.13 Million - $1.35 Million
59,518 Added 166.25%
95,318 $2.08 Billion
Q2 2023

Aug 14, 2023

BUY
$18.17 - $20.48 $650,486 - $733,184
35,800 New
35,800 $684 Million
Q4 2022

Feb 14, 2023

BUY
$14.96 - $17.39 $644,776 - $749,509
43,100 New
43,100 $691 Million

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $11.7B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Sherbrooke Park Advisers LLC Portfolio

Follow Sherbrooke Park Advisers LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sherbrooke Park Advisers LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sherbrooke Park Advisers LLC with notifications on news.